Allergy Immunotherapy Market to Touch Revenue Levels Bordering $4324.7 Mn By 2023
Market Research Future (MRFR)’s latest report reveals that the Global Allergy Immunotherapy Market is set to exhibit a steep rise in growth registering a CAGR of 10.85% during the forecast period 2017 to 2023. The market has been estimated to reach a valuation of USD 4,324.7 Mn by the end of 2023. The widespread prevalence of allergies has fueled demand in the allergy immunotherapy market. The trend is anticipated to perpetuate over the next couple of years. According to a report published by the World Health Organization (WHO), approximately 10-40% of the population was suffering from allergy in 2013. The increasing patient pool coupled with the availability of advanced allergy treatment procedures has augured well for the players of the allergy immunotherapy market. The market is expected to remain highly lucrative in the foreseeable future, and the increased investments in clinical trials and research & development activities are set to catapult the market on an upward trajectory. The developing healthcare sector in emerging markets in Latin America, Asia, etc. are anticipated to steer the growth of the allergy immunotherapy market. Other favorable factors encouraging the growth of the market include increasing awareness of the treatment, technological advancement, growth strategies of major players, etc. To Get Sample Report https://www.marketresearchfuture.com/sample_request/1517
visit
Key Players for Global Allergy Immunotherapy Market Market Research Future (MRFR) recognizes the following companies as the key players in Allergy Immunotherapy Market: There are plenty of large and small market players which operate in this market all over the globe. Some of the key players profiled in the report are ALK Abello A/S (Denmark), DBV Technologies (France), Stallergenes Greer (UK), HAL Allergy Group (Netherlands), Allergy Therapeutics (UK), Merck KGaA (Allergopharma) (Germany), and Circassia (UK) among others. Industry Developments: In August 2018, Arrayit Corporation, life sciences, and personalized medicine company announced its partnership with multiple providers of allergen immunotherapy products for allergy testing to treat patients with allergy and asthma. In August 2018, Astria Sunnyside Hospital announced the availability of an allergy testing and treatment program. Allergy treatment options being offered at the hospital include sublingual immunotherapy and regular allergy shots. Segments for Global Allergy Immunotherapy Market